Skip to content

Study · Randomized controlled trial · n = 1,500 · 2025

9 results

Long-term efficacy and safety of tirzepatide in participants with type 2 diabetes with inadequate glycaemic control on metformin and/or sulfonylurea: Post-hoc analysis of SURPASS-4.

Guan H, Jiang H, Yuan H, Sun J, Xu J, Ji L

Diabetes, obesity & metabolism9 Sept 2025Cited by 3 (Europe PMC)

PMID40926359 (opens in a new tab)PMCIDPMC12515763 (opens in a new tab)DOI10.1111/dom.70047 (opens in a new tab)PepBankPUB-40926359
Read at sourcePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on metformin and/or sulfonylurea, tirzepatide 5 mg lowered HbA1c more than insulin glargine at week 104.

    In plain wordsIn adults with type 2 diabetes, tirzepatide 5 mg lowered HbA1c more than insulin glargine over 104 weeks.

    Peptide
    Tirzepatide
    Outcome
    DecreaseHbA1c change at week 104 (5 mg)
    Study

    n = 1,500

    Comparator
    Insulin glargine
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5 mg · 104 weeksAs given in this study (human).

    Measurements

    HbA1c change
    −2.3%
    tirzepatide 5 mg
    HbA1c change
    −1%
    insulin glargine

    Source sentences

    Summary
    At Week 104, participants in the tirzepatide groups had significantly greater mean reduction in HbA1c (5 mg: -2.3%, 10 mg: -2.5%, 15 mg: -2.6%) compared with the insulin glargine group (-1.0%) (p < 0.001).
    2 context sentences
    Summary · context
    This post-hoc analysis was based on the SURPASS-4 data (NCT03730662), a multicenter, Phase III trial.
    Summary · context
    Participants were randomised to receive tirzepatide (5, 10, or 15 mg) or insulin glargine.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on metformin and/or sulfonylurea, tirzepatide 10 mg lowered HbA1c more than insulin glargine at week 104.

    In plain wordsIn adults with type 2 diabetes, tirzepatide 10 mg lowered HbA1c more than insulin glargine over 104 weeks.

    Peptide
    Tirzepatide
    Outcome
    DecreaseHbA1c change at week 104 (10 mg)
    Study

    n = 1,500

    Comparator
    Insulin glargine
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 mg · 104 weeksAs given in this study (human).

    Measurements

    HbA1c change
    −2.5%
    tirzepatide 10 mg
    HbA1c change
    −1%
    insulin glargine

    Source sentences

    Summary
    At Week 104, participants in the tirzepatide groups had significantly greater mean reduction in HbA1c (5 mg: -2.3%, 10 mg: -2.5%, 15 mg: -2.6%) compared with the insulin glargine group (-1.0%) (p < 0.001).
    2 context sentences
    Summary · context
    This post-hoc analysis was based on the SURPASS-4 data (NCT03730662), a multicenter, Phase III trial.
    Summary · context
    Participants were randomised to receive tirzepatide (5, 10, or 15 mg) or insulin glargine.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on metformin and/or sulfonylurea, tirzepatide 15 mg lowered HbA1c more than insulin glargine at week 104.

    In plain wordsIn adults with type 2 diabetes, tirzepatide 15 mg lowered HbA1c more than insulin glargine over 104 weeks.

    Peptide
    Tirzepatide
    Outcome
    DecreaseHbA1c change at week 104 (15 mg)
    Study

    n = 1,500

    Comparator
    Insulin glargine
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    15 mg · 104 weeksAs given in this study (human).

    Measurements

    HbA1c change
    −2.6%
    tirzepatide 15 mg
    HbA1c change
    −1%
    insulin glargine

    Source sentences

    Summary
    At Week 104, participants in the tirzepatide groups had significantly greater mean reduction in HbA1c (5 mg: -2.3%, 10 mg: -2.5%, 15 mg: -2.6%) compared with the insulin glargine group (-1.0%) (p < 0.001).
    2 context sentences
    Summary · context
    This post-hoc analysis was based on the SURPASS-4 data (NCT03730662), a multicenter, Phase III trial.
    Summary · context
    Participants were randomised to receive tirzepatide (5, 10, or 15 mg) or insulin glargine.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on metformin and/or sulfonylurea, tirzepatide 5 mg reduced body weight more than insulin glargine over 104 weeks.

    In plain wordsIn adults with type 2 diabetes, tirzepatide 5 mg reduced body weight, while weight rose with insulin glargine.

    Peptide
    Tirzepatide
    Outcome
    DecreaseBody weight change at week 104 (5 mg)
    Study

    n = 1,500

    Comparator
    Insulin glargine
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    5 mg · 104 weeksAs given in this study (human).

    Measurements

    Body weight change
    −7.6 kg
    tirzepatide 5 mg
    Body weight change
    2.1 kg
    insulin glargine

    Source sentences

    Summary
    Participants in the tirzepatide groups had significantly greater reduction in body weight (5 mg: -7.6 kg, 10 mg: -10.0 kg, 15 mg: -11.4 kg) compared with the insulin glargine group (2.1 kg) (p < 0.001).
    2 context sentences
    Summary · context
    This post-hoc analysis was based on the SURPASS-4 data (NCT03730662), a multicenter, Phase III trial.
    Summary · context
    Participants were randomised to receive tirzepatide (5, 10, or 15 mg) or insulin glargine.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on metformin and/or sulfonylurea, tirzepatide 10 mg reduced body weight more than insulin glargine over 104 weeks.

    In plain wordsIn adults with type 2 diabetes, tirzepatide 10 mg reduced body weight, while weight rose with insulin glargine.

    Peptide
    Tirzepatide
    Outcome
    DecreaseBody weight change at week 104 (10 mg)
    Study

    n = 1,500

    Comparator
    Insulin glargine
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    10 mg · 104 weeksAs given in this study (human).

    Measurements

    Body weight change
    −10 kg
    tirzepatide 10 mg
    Body weight change
    2.1 kg
    insulin glargine

    Source sentences

    Summary
    Participants in the tirzepatide groups had significantly greater reduction in body weight (5 mg: -7.6 kg, 10 mg: -10.0 kg, 15 mg: -11.4 kg) compared with the insulin glargine group (2.1 kg) (p < 0.001).
    2 context sentences
    Summary · context
    This post-hoc analysis was based on the SURPASS-4 data (NCT03730662), a multicenter, Phase III trial.
    Summary · context
    Participants were randomised to receive tirzepatide (5, 10, or 15 mg) or insulin glargine.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on metformin and/or sulfonylurea, tirzepatide 15 mg reduced body weight more than insulin glargine over 104 weeks.

    In plain wordsIn adults with type 2 diabetes, tirzepatide 15 mg reduced body weight, while weight rose with insulin glargine.

    Peptide
    Tirzepatide
    Outcome
    DecreaseBody weight change at week 104 (15 mg)
    Study

    n = 1,500

    Comparator
    Insulin glargine
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    15 mg · 104 weeksAs given in this study (human).

    Measurements

    Body weight change
    −11.4 kg
    tirzepatide 15 mg
    Body weight change
    2.1 kg
    insulin glargine

    Source sentences

    Summary
    Participants in the tirzepatide groups had significantly greater reduction in body weight (5 mg: -7.6 kg, 10 mg: -10.0 kg, 15 mg: -11.4 kg) compared with the insulin glargine group (2.1 kg) (p < 0.001).
    2 context sentences
    Summary · context
    This post-hoc analysis was based on the SURPASS-4 data (NCT03730662), a multicenter, Phase III trial.
    Summary · context
    Participants were randomised to receive tirzepatide (5, 10, or 15 mg) or insulin glargine.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on metformin and/or sulfonylurea, more participants on tirzepatide than on insulin glargine reached HbA1c below 7.0% at week 104.

    In plain wordsIn adults with type 2 diabetes, more people on tirzepatide than on insulin glargine reached an HbA1c below 7.0%.

    Peptide
    Tirzepatide
    Outcome
    IncreaseProportion achieving HbA1c below 7.0%
    Study

    n = 1,500

    Comparator
    Insulin glargine
    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5, 10 or 15 mg · 104 weeksAs given in this study (human).

    Source sentences

    Summary
    Significantly more participants in the tirzepatide group achieved HbA1c <7.0% compared with the insulin glargine group (p < 0.001).
    2 context sentences
    Summary · context
    This post-hoc analysis was based on the SURPASS-4 data (NCT03730662), a multicenter, Phase III trial.
    Summary · context
    Participants were randomised to receive tirzepatide (5, 10, or 15 mg) or insulin glargine.
  8. 08HumanRandomized controlled trialSafety outcome

    In adults with type 2 diabetes on metformin and/or sulfonylurea, hypoglycaemia was less frequent with tirzepatide than with insulin glargine.

    In plain wordsIn adults with type 2 diabetes, low blood sugar happened less often with tirzepatide than with insulin glargine.

    Peptide
    Tirzepatide
    Outcome
    DecreaseIncidence of hypoglycaemia
    Study

    n = 1,500

    Comparator
    Insulin glargine
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    5, 10 or 15 mg · 104 weeksAs given in this study (human).

    Source sentences

    Summary
    The incidence of hypoglycaemia was lower in the tirzepatide groups, and gastrointestinal AEs were mild or moderate in severity.
    2 context sentences
    Summary · context
    This post-hoc analysis was based on the SURPASS-4 data (NCT03730662), a multicenter, Phase III trial.
    Summary · context
    Participants were randomised to receive tirzepatide (5, 10, or 15 mg) or insulin glargine.
  9. 09HumanRandomized controlled trialSafety outcome

    In adults with type 2 diabetes on metformin and/or sulfonylurea, gastrointestinal adverse events with tirzepatide were mild or moderate in severity.

    In plain wordsIn adults with type 2 diabetes, stomach and gut side effects of tirzepatide were mild or moderate.

    Peptide
    Tirzepatide
    Outcome
    Not applicableSeverity of gastrointestinal adverse events
    Study

    n = 1,500

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    5, 10 or 15 mg · 104 weeksAs given in this study (human).

    Source sentences

    Summary
    gastrointestinal AEs were mild or moderate in severity.
    2 context sentences
    Summary · context
    This post-hoc analysis was based on the SURPASS-4 data (NCT03730662), a multicenter, Phase III trial.
    Summary · context
    Participants were randomised to receive tirzepatide (5, 10, or 15 mg) or insulin glargine.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.